About Ultimovacs
Ultimovacs is a small pharmaceutical company developing novel immunotherapy against cancer. Our leading product is UV1, a therapeutic cancer vaccine (TCV) directed against human telomerase (hTERT). The vaccine is a result of many years of pre-clinical and clinical research at the Norwegian Radium Hospital. UV1 is a synthetic peptide vaccine.
The peptides included in the vaccine is based on observation of immune responses in patients with advanced malignant disease surviving several years after vaccination with a hTERT based therapeutic cancer vaccine.
The company is focusing on two ongoing clinical trials where we are documenting safety and the vaccines ability to activate the immune system against cancer cells expressing the hTERT fragments that are the components of the vaccine.
Ultimovacs will also start a third clinical trial assessing safety and clinical outcomes when combining UV1 with ipilimumab in patients with malignant melanoma.
Ultimovacs is owned by Gjelsten Holding, The Norwegian Radium Hospital Research Foundation and Inven2 and is located in Oslo Science Park, Oslo, Norway.
Management
Øyvind K. Arnesen
Chief Executive Officer
MD with 10+ years of clinical experience and 10+ years of experience from pharma industry with positions as Medical Director Norway (Bristol-Myers Squibb), Medical Director and Head of Clinical Operations Nordic countries in Boehringer Ingelheim. Member of The National Commission for the Investigation of Research Misconduct in Norway. Board member of the Norwegian Pharmaceutical Industry Association.
Audun Tornes
Chief Operating Officer15+ years experience from pharma industry, incl. international line and project management positions in GE Healthcare. R&D management experience from big-pharma and start-ups. Inventor of more than 10 patents in diagnostics and cancer therapy.
Gustav Gaudernack
Chief Scientific OfficerProfessor and head of Unit for Immunotherapy at Radiumhospitalet from 1995 to 2011. Initiated over 20 clinical studies in cancer vaccination, including the first peptide vaccine study in cancer world wide (mutant RAS). Has more than 50 patents and 15 licenses of monoclonal antibodies, cancer vaccines and cancer diagnostics.
Solveig Brekke
Head Clinical Development & QAMSc in Pharmacy with 20 years of experience from clinical development and quality assurance in the pharma industry.
Board of Directors
Ketil Fjerdingen
(Chairman)
Bjørn Rune Gjelsten
Berit Gjelsten Haugen
Jonas Einarsson
